Corbalan R, et al. - Researchers investigated the management strategies and 1-year clinical outcomes of antithrombotic and congestive heart failure (CHF) therapies for patients with newly diagnosed atrial fibrillation (AF) with concomitant CHF stratified by etiology (ischemic cardiomyopathy [ICM] vs nonischemic cardiomyopathy [NICM]). In this cohort study of GARFIELD-AF registry, a prospective, noninterventional registry, 52,014 patients were included. As per outcomes, oral anticoagulants with or without antiplatelet drugs were less frequently used and antiplatelet drugs alone were more frequently used in patients with ischemic cardiomyopathy vs patients with nonischemic cardiomyopathy. Further, patients with ischemic cardiomyopathy had a worse outcome in terms of all-cause and cardiovascular death. These findings emphasize the necessity for enhanced adherence to guidelines-directed treatment of both atrial fibrillation and concomitant congestive heart failure, especially in patients with ischemic cardiomyopathy.